Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 32, Issue 19, 2014, Pages 2059-2066

  Langer, Corey J ^a   Olszanski, Anthony J ^b   Karp, Daniel D ^c   Benner, Rebecca J ^d   Scranton, Judith R ^d   Novello, Silvia ^e   Park, Keunchil ^f   Krzakowski, Maciej ^g   Jassem, Jacek ^h   Mok, Tony ⁱ  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d PFIZER INC   (United States)

^e UNIVERSITY OF TURIN   (Italy)

^f Sungkyunkwan University School of Medicine   (South Korea)

^g INSTITUTE OF ONCOLOGY   (Poland)

^h MEDICAL UNIVERSITY OF GDANSK   (Poland)

ⁱ CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; FIGITUMUMAB; HEMOGLOBIN A1C; PACLITAXEL; SOMATOMEDIN C;

ADENOSQUAMOUS CARCINOMA; ADULT; ADVANCED CANCER; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASTHENIA; BLEEDING; BODY WEIGHT DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARDIOPULMONARY INSUFFICIENCY; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEMOPTYSIS; HUMAN; HYPERGLYCEMIA; HYPOVOLEMIC SHOCK; KIDNEY FAILURE; LARGE CELL CARCINOMA; LEUKOPENIA; LIMB PAIN; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SEPTIC SHOCK; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN-LIKE GROWTH FACTOR I; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; TREATMENT OUTCOME;

EID: 84905867935     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.4932     Document Type: Article

References (14)

1. National Cancer Institute: PDQ Non-Small Cell Lung Cancer Treatment. Bethesda, MD, National Cancer Institute. http://www.cancer.gov/cancertopics/pdq/ treatment/non-small-cell-lung/healthprofessional (accessed October 20, 2011)
2. Pollak M: Targeting insulin and insulin-like growth factor signalling in oncology. Curr Opin Pharmacol 8:384-392, 2008
3. Fidler MJ, Shersher DD, Borgia JA, et al: Targeting the insulin-like growth factor receptor pathway in lung cancer: Problems and pitfalls. Ther Adv Med Oncol 4:51-60, 2012
4. Favoni RE, de Cupis A, Ravera F, et al: Expression and function of the insulin-like growth factor I system in human non-small-cell lung cancer and normal lung cell lines. Int J Cancer 56:858-866, 1994 (Pubitemid 24102754)
5. Kaiser U, Schardt C, Brandscheidt D, et al: Expression of insulin-like growth factor receptors I and II in normal human lung and in lung cancer. J Cancer Res Clin Oncol 119:665-668, 1993 (Pubitemid 23238149)
6. Haluska P, Shaw HM, Batzel GN, et al: Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 13:5834-5840, 2007 (Pubitemid 47583908)
7. Lacy MQ, Alsina M, Fonseca R, et al: Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol 26:3196-3203, 2008
8. Karp DD, Paz-Ares LG, Novello S, et al: Retraction: Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 30:4179, 2012
9. American Joint Committee on Cancer: AJCC Cancer Staging Manual (ed 6). New York, NY, Springer, 2002, pp 167-181
10. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
11. Sobin LH, Wittekind C (eds): International Union Against Cancer (UICC), TNM Classification of Malignant Tumours (ed 6). New York, NY, Wiley-Liss, 2002
12. Goto Y, Sekine I, Tanioka M, et al: Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer. Invest New Drugs 30:1548-1556, 2012
13. Murakami H, Doi T, Yamamoto N, et al: Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 70:407-414, 2012
14. Gualberto A, Pollak M: Emerging role of insulin-like growth factor receptor inhibitors in oncology: Early clinical trial results and future directions. Oncogene 28:3009-3021, 2009